Deutsche Bank Aktiengesellschaft Upgrades AstraZeneca (LON:AZN) to "Hold"

AstraZeneca (LON:AZN - Get Free Report) was upgraded by analysts at Deutsche Bank Aktiengesellschaft to a "hold" rating in a research note issued to investors on Monday, Marketbeat Ratings reports.

Several other research firms also recently weighed in on AZN. Barclays reissued an "overweight" rating and issued a £125 ($155.61) price target on shares of AstraZeneca in a research note on Monday, April 8th. UBS Group cut their price objective on shares of AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a "sell" rating for the company in a research report on Monday, February 12th. BMO Capital Markets restated an "outperform" rating on shares of AstraZeneca in a research report on Monday, February 12th. Shore Capital restated a "buy" rating on shares of AstraZeneca in a research report on Monday. Finally, JPMorgan Chase & Co. restated an "overweight" rating on shares of AstraZeneca in a research report on Thursday, April 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of £115.43 ($143.69).

AstraZeneca Price Performance

AZN traded down GBX 16 ($0.20) during midday trading on Monday, hitting £108.62 ($135.22). 1,747,567 shares of the company traded hands, compared to its average volume of 2,192,010. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70. The company has a market capitalization of £168.36 billion, a price-to-earnings ratio of 3,583.48, a PEG ratio of 0.89 and a beta of 0.19. AstraZeneca has a 52-week low of GBX 9,461 ($117.78) and a 52-week high of £123.92 ($154.26). The business has a 50 day simple moving average of £103.42 and a two-hundred day simple moving average of £104.22.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.